NIH R01 · 2024
ABSTRACT Current pharmacologic therapies for TMD pain are largely ineffective and plagued with side effects because their mechanisms of action to TMD pain have not been validated. Validation of potential pain targets for TMD pain can facilitate the development of mechanism-based approaches. Emerging evidence suggests that lysophosphatidic acid (LPA)/LPA receptor (LPAR) signaling is a promising target for spinally-mediated neuropathic pain. However, whether it contributes to trigeminally-mediated TMD pain, which involves anatomically and functionally unique target tissues and distinct etiology, is not known. In addition, there are several roadblocks which hamper the translatability of…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.